Palvella Therapeutics, Inc.
PVLAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePalvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company carries a $2.26B market cap, placing it firmly in the mid-cap category. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Market Cap
$2.26B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-23.06
EPS (TTM)
$-4.43
EPS (Fwd)
$-6.82
ROE
-34.3%
ROA
-16.6%
Cash
$261.9M
Total Debt
$20.4M
Free CF
-$21.6M
52W Change
432.8%
Annual Financials
Cash vs Debt
Palvella Therapeutics, Inc. holds $261.9M in cash against $20.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$21.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -34.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing PVLA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.